The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial

Nursing home-associated pneumonia (NHAP) is a common type of infection among long-term care residents. Moreover, the mortality of NHAP is also higher than community-acquired pneumonia (CAP). In traditional Chinese medicine (TCM), the decoctions of Banxia Houpo Tang (BHT) and Ding Chuan Tang (DCT) ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of ethnopharmacology 2024-01, Vol.318, p.117017-117017, Article 117017
Hauptverfasser: Chen, Yun-Tai, Chen, Pei-Hsin, Chou, Fang-Yu, Lin, Sheng-Hao, Huang, Sung-Yen, Lee, Ming-Chung, Chang, Yu-Jun, Hsu, Po-Chi, Lo, Lun-Chien
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117017
container_issue
container_start_page 117017
container_title Journal of ethnopharmacology
container_volume 318
creator Chen, Yun-Tai
Chen, Pei-Hsin
Chou, Fang-Yu
Lin, Sheng-Hao
Huang, Sung-Yen
Lee, Ming-Chung
Chang, Yu-Jun
Hsu, Po-Chi
Lo, Lun-Chien
description Nursing home-associated pneumonia (NHAP) is a common type of infection among long-term care residents. Moreover, the mortality of NHAP is also higher than community-acquired pneumonia (CAP). In traditional Chinese medicine (TCM), the decoctions of Banxia Houpo Tang (BHT) and Ding Chuan Tang (DCT) are two formulas supporting the lungs' natural defense systems, helps to expel mucus and promote detoxification. We designed a concentrated Chinese herbal extract formula called BDT1, that combines the compounds of BHT and DCT. In this study, we evaluated the safety and efficacy of BDT1 for NHAP prevention in high-risk older residents in the nursing home. In this randomized, double-blind, placebo-controlled trial, 160 participants aged over 65 years old living in the nursing home were randomly assigned 1:1 to the BDT1 and placebo group. Besides regular medicine, participants received either BDT1 or a placebo for 12 consecutive weeks. The primary outcome was the hospitalization rate for pneumonia in the intervention period and half-year follow-up. The microscopic examination of Gram-stained sputum was also evaluated before and after the trial. Data were analyzed by using the Chi-square test and Wilcoxon Signed Ranks Test with SPSS. A total of 160 participants were enrolled into two study groups in this study, which was completed with 143 participants analyzed, including 70 subjects in the BDT1 group and 73 subjects in the placebo group. After the 12-week medical treatment, the hospitalization rate for pneumonia was 10.0% and 34.2% in the BDT1 and placebo group respectively. The risk of pneumonia in half a year was lower in the BDT1 group (adjusted hazard ratio = 0.422, 95% CI = 0.226–0.791). Compared to the placebo group, the level of Gram-negative bacilli in the BDT1 group is significantly declined in sputum samples (p 
doi_str_mv 10.1016/j.jep.2023.117017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2850313799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378874123008851</els_id><sourcerecordid>2850313799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-5ae614fa675d722aa81f8aab207435dc2cd6e90e7c42fa3681e8d582f202a5bf3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EokvhAbigOXIgi_8kcRZO1QoKUiUu5Ww59rjxktjBTiptX4jXxKstPXKxJc8334y_HyFvGd0yytqPh-0B5y2nXGwZk5TJZ2TDOskr2UjxnGyokF3VyZpdkFc5HyilktX0JbkQsml53fIN-XM7IGTtcDmCDhbQOW-0OUJ0sB98wIwwYOr1CBNab8oLuJhgDrhOMXgNc8J7DIuPAXyAwd8NVfL5F-BoMUHC7G0p51NxKbPCmrIPdzDECT_BFaQyNU7-Ae0HsHHtR6z60ZdNTDnLKiMsyevxNXnh9JjxzeN9SX5-_XK7_1bd_Lj-vr-6qYxoxFI1GltWO93KxkrOte6Y67TuOZW1aKzhxra4oyhNzZ0Wbcews03HXQlRN70Tl-T92XdO8feKeVGTzwbHUQeMa1a8a6hgQu52RcrOUpNizgmdmpOfdDoqRtWJjzqowked-Kgzn9Lz7tF-7UueTx3_gBTB57MAyyfvPSaVjcdgSvYJzaJs9P-x_wsQ7aNT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2850313799</pqid></control><display><type>article</type><title>The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial</title><source>Access via ScienceDirect (Elsevier)</source><creator>Chen, Yun-Tai ; Chen, Pei-Hsin ; Chou, Fang-Yu ; Lin, Sheng-Hao ; Huang, Sung-Yen ; Lee, Ming-Chung ; Chang, Yu-Jun ; Hsu, Po-Chi ; Lo, Lun-Chien</creator><creatorcontrib>Chen, Yun-Tai ; Chen, Pei-Hsin ; Chou, Fang-Yu ; Lin, Sheng-Hao ; Huang, Sung-Yen ; Lee, Ming-Chung ; Chang, Yu-Jun ; Hsu, Po-Chi ; Lo, Lun-Chien</creatorcontrib><description>Nursing home-associated pneumonia (NHAP) is a common type of infection among long-term care residents. Moreover, the mortality of NHAP is also higher than community-acquired pneumonia (CAP). In traditional Chinese medicine (TCM), the decoctions of Banxia Houpo Tang (BHT) and Ding Chuan Tang (DCT) are two formulas supporting the lungs' natural defense systems, helps to expel mucus and promote detoxification. We designed a concentrated Chinese herbal extract formula called BDT1, that combines the compounds of BHT and DCT. In this study, we evaluated the safety and efficacy of BDT1 for NHAP prevention in high-risk older residents in the nursing home. In this randomized, double-blind, placebo-controlled trial, 160 participants aged over 65 years old living in the nursing home were randomly assigned 1:1 to the BDT1 and placebo group. Besides regular medicine, participants received either BDT1 or a placebo for 12 consecutive weeks. The primary outcome was the hospitalization rate for pneumonia in the intervention period and half-year follow-up. The microscopic examination of Gram-stained sputum was also evaluated before and after the trial. Data were analyzed by using the Chi-square test and Wilcoxon Signed Ranks Test with SPSS. A total of 160 participants were enrolled into two study groups in this study, which was completed with 143 participants analyzed, including 70 subjects in the BDT1 group and 73 subjects in the placebo group. After the 12-week medical treatment, the hospitalization rate for pneumonia was 10.0% and 34.2% in the BDT1 and placebo group respectively. The risk of pneumonia in half a year was lower in the BDT1 group (adjusted hazard ratio = 0.422, 95% CI = 0.226–0.791). Compared to the placebo group, the level of Gram-negative bacilli in the BDT1 group is significantly declined in sputum samples (p &lt; 0.05). In conclusion, the cumulative incidence of pneumonia and related-hospitalization rates declined significantly after 12-weeks of BDT1 treatment. Besides, Chinese herbal medicine BDT1 is a safe therapy without hepatotoxicity or nephrotoxicity. [Display omitted]</description><identifier>ISSN: 0378-8741</identifier><identifier>EISSN: 1872-7573</identifier><identifier>DOI: 10.1016/j.jep.2023.117017</identifier><identifier>PMID: 37562462</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Chinese herbal medicine ; Clinical trial ; Efficacy ; Long-term care ; Nursing home-associated pneumonia (NHAP)</subject><ispartof>Journal of ethnopharmacology, 2024-01, Vol.318, p.117017-117017, Article 117017</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-5ae614fa675d722aa81f8aab207435dc2cd6e90e7c42fa3681e8d582f202a5bf3</citedby><cites>FETCH-LOGICAL-c353t-5ae614fa675d722aa81f8aab207435dc2cd6e90e7c42fa3681e8d582f202a5bf3</cites><orcidid>0000-0002-1433-6002 ; 0000-0001-9691-3872</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jep.2023.117017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37562462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Yun-Tai</creatorcontrib><creatorcontrib>Chen, Pei-Hsin</creatorcontrib><creatorcontrib>Chou, Fang-Yu</creatorcontrib><creatorcontrib>Lin, Sheng-Hao</creatorcontrib><creatorcontrib>Huang, Sung-Yen</creatorcontrib><creatorcontrib>Lee, Ming-Chung</creatorcontrib><creatorcontrib>Chang, Yu-Jun</creatorcontrib><creatorcontrib>Hsu, Po-Chi</creatorcontrib><creatorcontrib>Lo, Lun-Chien</creatorcontrib><title>The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial</title><title>Journal of ethnopharmacology</title><addtitle>J Ethnopharmacol</addtitle><description>Nursing home-associated pneumonia (NHAP) is a common type of infection among long-term care residents. Moreover, the mortality of NHAP is also higher than community-acquired pneumonia (CAP). In traditional Chinese medicine (TCM), the decoctions of Banxia Houpo Tang (BHT) and Ding Chuan Tang (DCT) are two formulas supporting the lungs' natural defense systems, helps to expel mucus and promote detoxification. We designed a concentrated Chinese herbal extract formula called BDT1, that combines the compounds of BHT and DCT. In this study, we evaluated the safety and efficacy of BDT1 for NHAP prevention in high-risk older residents in the nursing home. In this randomized, double-blind, placebo-controlled trial, 160 participants aged over 65 years old living in the nursing home were randomly assigned 1:1 to the BDT1 and placebo group. Besides regular medicine, participants received either BDT1 or a placebo for 12 consecutive weeks. The primary outcome was the hospitalization rate for pneumonia in the intervention period and half-year follow-up. The microscopic examination of Gram-stained sputum was also evaluated before and after the trial. Data were analyzed by using the Chi-square test and Wilcoxon Signed Ranks Test with SPSS. A total of 160 participants were enrolled into two study groups in this study, which was completed with 143 participants analyzed, including 70 subjects in the BDT1 group and 73 subjects in the placebo group. After the 12-week medical treatment, the hospitalization rate for pneumonia was 10.0% and 34.2% in the BDT1 and placebo group respectively. The risk of pneumonia in half a year was lower in the BDT1 group (adjusted hazard ratio = 0.422, 95% CI = 0.226–0.791). Compared to the placebo group, the level of Gram-negative bacilli in the BDT1 group is significantly declined in sputum samples (p &lt; 0.05). In conclusion, the cumulative incidence of pneumonia and related-hospitalization rates declined significantly after 12-weeks of BDT1 treatment. Besides, Chinese herbal medicine BDT1 is a safe therapy without hepatotoxicity or nephrotoxicity. [Display omitted]</description><subject>Chinese herbal medicine</subject><subject>Clinical trial</subject><subject>Efficacy</subject><subject>Long-term care</subject><subject>Nursing home-associated pneumonia (NHAP)</subject><issn>0378-8741</issn><issn>1872-7573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQxi0EokvhAbigOXIgi_8kcRZO1QoKUiUu5Ww59rjxktjBTiptX4jXxKstPXKxJc8334y_HyFvGd0yytqPh-0B5y2nXGwZk5TJZ2TDOskr2UjxnGyokF3VyZpdkFc5HyilktX0JbkQsml53fIN-XM7IGTtcDmCDhbQOW-0OUJ0sB98wIwwYOr1CBNab8oLuJhgDrhOMXgNc8J7DIuPAXyAwd8NVfL5F-BoMUHC7G0p51NxKbPCmrIPdzDECT_BFaQyNU7-Ae0HsHHtR6z60ZdNTDnLKiMsyevxNXnh9JjxzeN9SX5-_XK7_1bd_Lj-vr-6qYxoxFI1GltWO93KxkrOte6Y67TuOZW1aKzhxra4oyhNzZ0Wbcews03HXQlRN70Tl-T92XdO8feKeVGTzwbHUQeMa1a8a6hgQu52RcrOUpNizgmdmpOfdDoqRtWJjzqowked-Kgzn9Lz7tF-7UueTx3_gBTB57MAyyfvPSaVjcdgSvYJzaJs9P-x_wsQ7aNT</recordid><startdate>20240110</startdate><enddate>20240110</enddate><creator>Chen, Yun-Tai</creator><creator>Chen, Pei-Hsin</creator><creator>Chou, Fang-Yu</creator><creator>Lin, Sheng-Hao</creator><creator>Huang, Sung-Yen</creator><creator>Lee, Ming-Chung</creator><creator>Chang, Yu-Jun</creator><creator>Hsu, Po-Chi</creator><creator>Lo, Lun-Chien</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1433-6002</orcidid><orcidid>https://orcid.org/0000-0001-9691-3872</orcidid></search><sort><creationdate>20240110</creationdate><title>The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial</title><author>Chen, Yun-Tai ; Chen, Pei-Hsin ; Chou, Fang-Yu ; Lin, Sheng-Hao ; Huang, Sung-Yen ; Lee, Ming-Chung ; Chang, Yu-Jun ; Hsu, Po-Chi ; Lo, Lun-Chien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-5ae614fa675d722aa81f8aab207435dc2cd6e90e7c42fa3681e8d582f202a5bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chinese herbal medicine</topic><topic>Clinical trial</topic><topic>Efficacy</topic><topic>Long-term care</topic><topic>Nursing home-associated pneumonia (NHAP)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Yun-Tai</creatorcontrib><creatorcontrib>Chen, Pei-Hsin</creatorcontrib><creatorcontrib>Chou, Fang-Yu</creatorcontrib><creatorcontrib>Lin, Sheng-Hao</creatorcontrib><creatorcontrib>Huang, Sung-Yen</creatorcontrib><creatorcontrib>Lee, Ming-Chung</creatorcontrib><creatorcontrib>Chang, Yu-Jun</creatorcontrib><creatorcontrib>Hsu, Po-Chi</creatorcontrib><creatorcontrib>Lo, Lun-Chien</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ethnopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Yun-Tai</au><au>Chen, Pei-Hsin</au><au>Chou, Fang-Yu</au><au>Lin, Sheng-Hao</au><au>Huang, Sung-Yen</au><au>Lee, Ming-Chung</au><au>Chang, Yu-Jun</au><au>Hsu, Po-Chi</au><au>Lo, Lun-Chien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial</atitle><jtitle>Journal of ethnopharmacology</jtitle><addtitle>J Ethnopharmacol</addtitle><date>2024-01-10</date><risdate>2024</risdate><volume>318</volume><spage>117017</spage><epage>117017</epage><pages>117017-117017</pages><artnum>117017</artnum><issn>0378-8741</issn><eissn>1872-7573</eissn><abstract>Nursing home-associated pneumonia (NHAP) is a common type of infection among long-term care residents. Moreover, the mortality of NHAP is also higher than community-acquired pneumonia (CAP). In traditional Chinese medicine (TCM), the decoctions of Banxia Houpo Tang (BHT) and Ding Chuan Tang (DCT) are two formulas supporting the lungs' natural defense systems, helps to expel mucus and promote detoxification. We designed a concentrated Chinese herbal extract formula called BDT1, that combines the compounds of BHT and DCT. In this study, we evaluated the safety and efficacy of BDT1 for NHAP prevention in high-risk older residents in the nursing home. In this randomized, double-blind, placebo-controlled trial, 160 participants aged over 65 years old living in the nursing home were randomly assigned 1:1 to the BDT1 and placebo group. Besides regular medicine, participants received either BDT1 or a placebo for 12 consecutive weeks. The primary outcome was the hospitalization rate for pneumonia in the intervention period and half-year follow-up. The microscopic examination of Gram-stained sputum was also evaluated before and after the trial. Data were analyzed by using the Chi-square test and Wilcoxon Signed Ranks Test with SPSS. A total of 160 participants were enrolled into two study groups in this study, which was completed with 143 participants analyzed, including 70 subjects in the BDT1 group and 73 subjects in the placebo group. After the 12-week medical treatment, the hospitalization rate for pneumonia was 10.0% and 34.2% in the BDT1 and placebo group respectively. The risk of pneumonia in half a year was lower in the BDT1 group (adjusted hazard ratio = 0.422, 95% CI = 0.226–0.791). Compared to the placebo group, the level of Gram-negative bacilli in the BDT1 group is significantly declined in sputum samples (p &lt; 0.05). In conclusion, the cumulative incidence of pneumonia and related-hospitalization rates declined significantly after 12-weeks of BDT1 treatment. Besides, Chinese herbal medicine BDT1 is a safe therapy without hepatotoxicity or nephrotoxicity. [Display omitted]</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37562462</pmid><doi>10.1016/j.jep.2023.117017</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-1433-6002</orcidid><orcidid>https://orcid.org/0000-0001-9691-3872</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0378-8741
ispartof Journal of ethnopharmacology, 2024-01, Vol.318, p.117017-117017, Article 117017
issn 0378-8741
1872-7573
language eng
recordid cdi_proquest_miscellaneous_2850313799
source Access via ScienceDirect (Elsevier)
subjects Chinese herbal medicine
Clinical trial
Efficacy
Long-term care
Nursing home-associated pneumonia (NHAP)
title The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A28%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20safety%20and%20efficacy%20of%20Chinese%20herbal%20medicine%20for%20pneumonia%20prevention%20in%20high-risk%20elder%20residents%20in%20the%20nursing%20home:%20A%20randomized,%20double-blind%20clinical%20trial&rft.jtitle=Journal%20of%20ethnopharmacology&rft.au=Chen,%20Yun-Tai&rft.date=2024-01-10&rft.volume=318&rft.spage=117017&rft.epage=117017&rft.pages=117017-117017&rft.artnum=117017&rft.issn=0378-8741&rft.eissn=1872-7573&rft_id=info:doi/10.1016/j.jep.2023.117017&rft_dat=%3Cproquest_cross%3E2850313799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2850313799&rft_id=info:pmid/37562462&rft_els_id=S0378874123008851&rfr_iscdi=true